 |
|
|
| |
Once Daily Sofosbuvir (GS-7977) plus PEG/RBV In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection: The ATOMIC Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Tarek Hassanein1, Eric Lawitz2, Israel Crespo3, Mitchell Davis4, Michael P. DeMicco5, David R. Nelson6, David Eric Bernstein7, Nezam Afdhal8, Ira M. Jacobson9, John M. Vierling10, Stuart C. Gordon11, Jane Anderson12, Robert H. Hyland12, Robert Hindes12, William T. Symonds12, Evguenia S. Svarovskaia12, Di An12, Efsevia Albanis13, Sanjeev Arora14, Kris V. Kowdley15; for the ATOMIC Investigators
1 Southern California Liver Centers, Coronado, CA; 2 Alamo Medical Research, San Antonio, TX; 3 Advanced Research Institute, Trinity, FL; 4 South Florida Center of Gastroenterology, Wellington, FL; 5 Advanced Clinical Research Institute, Anaheim, CA; 6 University of Florida, Gainesville, FL; 7 North Shore University Hospital, Manhasset, NY; 8 Beth Israel Deaconess Medical Center, Boston, MA; 9 Weill Cornell Medical College, New York, NY; 10 Baylor College of Medicine, Houston, TX; 11 Henry Ford Health Systems, Detroit, MI; 12 Gilead Sciences, Inc., Foster City, CA; 13 Mt. Sinai School of Medicine, New York, NY; 14 University of New Mexico, Albuquerque, NM; 15 Virginia Mason Medical Center, Seattle, WA
|
| |
|
|
|
|
|
